Sustained immunological effects of Glatiramer acetate in patients with multiple sclerosis treated for over 6 years
- 1 September 2002
- journal article
- clinical trial
- Published by Elsevier in Journal of the Neurological Sciences
- Vol. 201 (1-2) , 71-77
- https://doi.org/10.1016/s0022-510x(02)00201-0
Abstract
No abstract availableKeywords
This publication has 31 references indexed in Scilit:
- Glatiramer acetate induces a Th2-biased response and crossreactivity with myelin basic protein in patients with MSMultiple Sclerosis Journal, 2001
- Long-term therapy with glatiramer acetate in multiple sclerosis: effect on T-cellsMultiple Sclerosis Journal, 2001
- Glatiramer acetate (Copaxone®) induces degenerate, Th2-polarized immune responses in patients with multiple sclerosisJournal of Clinical Investigation, 2000
- Copolymer 1 inhibits chronic relapsing experimental allergic encephalomyelitis induced by proteolipid protein (PLP) peptides in mice and interferes with PLP-specific T cell responsesJournal of Neuroimmunology, 1996
- Copolymer 1 reduces relapse rate and improves disability in relapsing‐remitting multiple sclerosisNeurology, 1995
- T suppressor hybridomas and interleukin‐2‐dependent lines induced by copolymer 1 or by spinal cord homogenate down‐regulate experimental allergic encephalomyelitisEuropean Journal of Immunology, 1993
- Antigen-driven bystander suppression after oral administration of antigens.The Journal of Experimental Medicine, 1991
- A Pilot Trial of Cop 1 in Exacerbating–Remitting Multiple SclerosisNew England Journal of Medicine, 1987
- Suppression of experimental allergic encephalomyelitis in rhesus monkeys by a synthetic basic copolymerClinical Immunology and Immunopathology, 1974
- Suppression of experimental allergic encephalomyelitis by a synthetic polypeptideEuropean Journal of Immunology, 1971